Back to today’s briefing

Story perspectives

Breakthrough Therapy Slows Huntington's Disease Progression by 75%

10/3/2025

23 5 Full Breakdown

Summary

Story summary

AMT-130 slowed Huntington’s disease progression by 75% in 24 participants.
It requires brain surgery lasting 8–10 hours and is not FDA-approved.
Huntington’s disease results from an HTT gene mutation and typically begins at 30–50.
Experts caution costs and access may be limited even if approved.
FDA may grant accelerated approval by end of 2026; Huntington’s therapies are in development.

1 of 1

Story summary

AMT-130 slowed Huntington’s disease progression by 75% in 24 participants.
It requires brain surgery lasting 8–10 hours and is not FDA-approved.
Huntington’s disease results from an HTT gene mutation and typically begins at 30–50.
Experts caution costs and access may be limited even if approved.
FDA may grant accelerated approval by end of 2026; Huntington’s therapies are in development.